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Summary The relation between the use of combination oral contraceptives (OCs) and the risk of epithelial
ovarian cancer was investigated in a case-control study conducted in Milan on 209 women below the age of
60 with histologically confirmed epithelial ovarian cancer, and 418 age-matched controls with a spectrum of
acute conditions apparently unrelated to OC use. Combination oral contraceptives were used by 18 (9%)
cases, and 59 (14%) controls, giving a relative risk estimate of 0.6 (95% confidence interval=0.3-1.0,
P<0.05). The risk of ovarian cancer decreased with increasing duration of use and the point estimate
remained below unity long after cessation ofuse. These results were not accounted for by parity, infertility, or
other identified potential confounding factors. Thus, the findings of the present study add further support to
the evidence emerging from American data of a reduction of -40% in the risk of epithelial ovarian cancer
among women who had used oral contraceptives.
Evidence from several case-control studies
conducted mainly in North America (McGowan et
al., 1979; Annegers et al., 1979; Hildreth et al., 1981;
Weiss et al., 1981; Willett et al., 1981; Rosenberg et
al., 1982; Cramer et al., 1982; Casagrande et al.,
1983; Centers for Disease Control Cancer and
Steroid Hormone Study, 1983; see also Newhouse et
al., 1977) suggests that the use of cQmbined oral
contraceptives (OCs) reduces the risk of epthelial
ovarian cancer. General lifestyle and reproductive
characteristics, however, are notoriously different in
Italy. Oral contraceptive use, in particular, is less
common and usually concentrated in the younger
age groups. It is, therefore, of interest to re-evaluate
the relation of OC use to the risk of ovarian cancer
in such a population. This has been done in the
present study, using data from a case-control study
conducted in Milan.
Subjects and methods
Since 1979, we have conducted a case-control study
of ovarian cancer (Franceschi et al., 1982). Trained
interviewers identify and question women admitted
for ovarian cancer and for a wide spectrum of other
conditions to University and General Hospitals in
the Greater Milan area. On the average, <2% of
the eligible women (cases or controls) refuse to be
interviewed.
A standard questionnaire is used to obtain
information on personal characteristics and habits,
gynaecological and obstetric data, related medical
history and history of lifetime use of oral
contraceptives and other female hormones.
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The present study is based on data obtained
before September 30, 1983.
Cases
The cases studied were women with histologically
confirmed epithelial ovarian cancer, diagnosed
within the year prior to interview, admitted to the
First Obstetrics and Gynaecology Clinic of the
University and to the National Cancer Institute of
Milan. There were 209 women younger than 60
years who met these criteria. The histological type
was serous carcinoma in 61%, endometrioid
carcinoma in 13%, mucinous carcinoma in 13%,
clear cell carcinoma in 6%, and undifferentiated
carcinoma in 7%.
Controls
Potential controls were all women below the age of
60 years whose primary diagnosis was judged to be
unrelated to any of the established or suspected risk
factors for ovarian cancer. Women were not eligible
if they were admitted for gynaecological, hormonal
or neoplastic diseases, or had undergone bilateral
oophorectomy. The pool of potential controls was
reduced by selecting at random two controls per
case from the same 5-year age group. Of the final
control series (418 patients) 45% had musculo-
skeletal diseases (trauma or other orthopaedic
conditions), 23% were admitted for acute abdominal
disorders that generally required operations, and
32% had other illnesses, such as ear, nose and
throat, or teeth disorders.
Data analysis
We estimated the odds ratios (as estimators of the
relative risk, RR; Fleiss, 1981) of ovarian cancer,
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together with their 95% approximate confidence
intervals (CI) (Miettinen, 1976) among women who
used oral contraceptives relative to women who had
never used them. The significance of the linear trend
in the risk according to the duration of use was
assessed using the test given by Mantel (1963).
Nulliparity, late age at first birth and later
menopause were more frequent among the cases
than the controls. These and other (see below -
variables included in the regression) potential
confounding factors were first controlled
individually using stratification and the Mantel-
Haenszel procedure (Mantel & Haenszel, 1959);
secondly, they were simultaneously controlled by
means of multiple logistic regression, fitted by the
method of maximum likelihood (Breslow & Day,
1980). Included in the regression equations, apart
from various measures of oral contraceptive use,
were terms for age, marital status, education, parity,
age at first birth, age at menopause, body mass
index, cigarette smoking, coffee drinking habits,
treatments for sterility and use of female hormones
for menopausal replacement therapy or other
reasons.
Results
Overall, 18 (9%) women with ovarian cancer, and
59 (14%) controls had at one time used oral
contraceptives. The crude RR estimate for ever
versus never use is, therefore, 0.6 (95% CI=0.3-1.0,
1=3.91, P=0.05; Table I). The risk of developing
ovarian cancer decreased with increasing duration
of OC use, the point estimate declining to 0.4 for
Table I Distribution of 209 cases of epithelial ovarian
cancer and 418 controls according to use, and duration of
use of combination oral contraceptives. Milan, Italy
1979-83.
RR
Ovarian estimate
cancer Controls (95% CI)
Oral contraceptivesa
Never 191 359 1.0b
Ever 18 59 0.6
(0.3-1.0)
Duration of use (years)c
Nonuser 191 359 1.0b
<2 13 34 0.7
(0.4-1.4)
2 5 25 0.4
(0.1-1.0)
,X2 =3.91, P =0.05.
bReference category.
CX (trend)=4.85, P=0.03.
women who had used oral contraceptives for 2 or
more years. This trend in risk was statistically
significant (X2 =4.85, P=0.03).
The reduced RR appeared to be long lasting, as
measured by both time since first use ('latency') and
time since last use ('recency') (Table II). Whereas
the risk estimate was apparently lower in current
users (RR=0.3, based on three cases and 19
controls only), there was no clear trend of risk
within strata of time since first OC use, the point
estimate remaining 0.6 for women who had ceased
usage more than 6 years before. These findings could
not simply be explained by different duration of use
as the point estimates for latency or recency
remained below unity in the various strata of
duration considered.
Table II Distributions of 209 cases of epithelial ovarian
cancer and 418 controls according to latency and recency
of oral contraceptive (OC) use. Milan, Italy, 1979-83.
Ovarian RR
cancer Controls estimate
Time sincefirst OC use
(years)
Nonuser 191 359 1.0a
<10 11 39 0.5
>10 7 20 0.7
Time since last OC use
(years)
Nonuser 191 359 1.Oa
<2 3 19 0.3
2-6 7 16 0.8
>6 8 24 0.6
aReference category.
The decreased risk of ovarian cancer among ever
users was consistent across strata of age, parity and
gravidity (data not shown, as similar to parity) and
age at first birth (Table III). The protection,
however, was apparently confined to women who
had used the pill after first full term pregnancy with
a risk estimate of 0.2, while the relative risk was 1.0
for OC use before first birth (Table IV). These two
estimates, nonetheless, were not significantly
different, as their confidence intervals overlapped.
Oral contraceptive use was compared within strata
of marital status, education, cigarette smoking,
menopausal status and age at menopause. There
was no indication that the protection was confined
to any particular sub-group. Likewise, the results
were practically unchanged when a large number of
factors were taken into account by means of
multiple logistic regression. Moreover, to assess the
potential confounding effect of infertility or sub-ORAL CONTRACEPTIVES AND OVARIAN CANCER 33
Table III Distribution of 209 cases of epithelial ovarian cancer and 418
controls according to ever use of oral contraceptives, age, parity, and age at
first birth. Milan, Italy, 1979-83.
Ovarian cancer
User Nonuser
Controls
RR
User Nonuser estimate
Age
<35 3 17 16 24 0.3
35-49 12 83 36 156 0.6
>50 3 91 7 179 0.8
Parity
0 9 54 13 67 0.9
1-2 7 105 32 202 0.4
,>3 2 32 14 90 0.4
Age atfirst birth
<25 3 43 19 145 0.5
>25 6 94 27 147 0.3
Table IV Relative risk estimates of epithelial ovarian
cancer in relation to use of oral contraceptives (OCs)
before and after first birth.
RR
Ovarian estimate
cancer Controls (95% CI)
OC use beforefirst birth
Never 191 359 1.0a
Ever 14 19 1.0b
(0.4-2.1)
OC use afterfirst birthc
Never 137 292 1.0a
Ever 4 40 0.2c
(0.1-0.6)
aReference category.
bAdjusted for parity.
cParous women only.
fertility on the relation between OCs and ovarian
cancer, we evaluated the pattern of use of female
hormones for the treatment of infertility or
menstrual irregularities: there was no material
difference between cases and controls.
Discussion
The results of this study again confirm that
combination oral contraceptives confer some
protection against the occurrence of epithelial
ovarian cancer, women who had ever used them
experiencing a relative risk of ovarian cancer
significantly lower than non-users. The reduction
was greater for women who had used OCs for
longer periods and the lowered risk apparently
persisted long after OC use ceased. It is unlikely
that biased recall due to knowledge of the
hypothesis explains our findings. At the time of
data collection, the posssible protection given by
the pill on the risk of ovarian cancer had not
gained widespread attention in the lay press in Italy
and was almost certainly unknown to the great
majority of the subjects interviewed. In the present
study, low 'parity or infertility did not seem to
explain this protection, as the risk estimates were
decreased in each stratum of parity considered and
the use of hormonal treatments for sterility was not
materially different in cases and in controls. With
regard to other confoundings, the risk estimates
were virtually unaffected when a large number of
potential distorting factors were taken into account
by means of multiple regression.
In this study protection was apparently confined
to women who had used oral contraceptives after
first birth. It is still possible that the difference
between OC use before or after first birth was
simply due to chance, as the confidence intervals of
the estimates overlapped. However, modifications
induced by first full term pregnancy at different ages
have a clear influence on ovarian cancer risk (La
Vecchia et al., 1983). This topic, therefore,. is of
potential interest, and warrants further analysis.
In conclusion, the findings of the present study
add further support to the evidence, emerging
mainly from American data (McGowan et al., 1979;
Annegers et al., 1979; Hildreth et al., 1981; Weiss et
al., 1981; Willett et al., 1981; Rosenberg et al., 1982;
Cramer et al., 1982; Casagrande et al., 1983; Centers
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Study, 1983), of a reduction of -40% in the risk of
epithelial ovarian cancer among women who had
used oral contraceptives. This result is statistically
significant, even with a considerably lower
proportion of ever users (15% in the comparison
group of this series versus 30-60% in American
series of comparable age, Rosenberg et al., 1982;
Centers for Disease Control Cancer and Steroid
Hormone Study, 1983), and with a shorter average
duration of use. Oral contraceptive use, moreover,
was essentially concentrated in the younger age
groups, but the protective effect was evident for all
the subsequent age strata considered.
As a biological correlate of this epidemiological
finding, it has been suggested that oral
contraceptives might confer protection against
ovarian cancer simply by inhibiting ovulation. A
few criticisms, however, have been made to the
model which relates the risk of ovarian cancer to the
simple duration of ovulatory activity, mainly based
on the different effect of the first term pregnancy at
different ages, age at first birth being apparently
more strongly associated with the risk of ovarian
cancer than the actual number of births (La
Vecchia et al., 1983). Alternatively, the reduction of
pituitary gonadotropin secretion (which reportedly
stimulates growth of cell lines derived from human
ovarian carcinomas, Simon et al., 1983) might well
explain the negative association between
combination oral contraceptives and the risk of
ovarian cancer.
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